Compare Enveric Biosciences Inc (ENVB) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs NextEra Energy, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while NextEra Energy, Inc. trades at $77.32 (market cap $161.39B). The key difference: NextEra Energy, Inc. is far larger — about 23733.8× Enveric Biosciences Inc's market cap, and NextEra Energy, Inc. pays a 3.22% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and NextEra Energy, Inc. for 83 Days on average.
| ENVB | NEE | |
|---|---|---|
Market Cap | $6.80M | $161.39B |
Volume | 64,867 | 11,780,955 |
Sector | Health | Utilities |
52-Week High | $10.80 | $97.88 |
52-Week Low | $1.27 | $75.49 |
Typical Hold Time | 14 Days | 83 Days |
Enterprise Value | -$1.49M | $268.72B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
NextEra Energy (NEE) trades at $77.06, down 1.05% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a 32.4% net income margin and consistent earnings beats in recent quarters, though it missed in Q4 2025. Recent news highlights growth initiatives, including a $22.3 billion energy infrastructure project in Texas announced on September 30, 2026.
The outlook remains positive with a consensus price target of $96.00, implying 25% upside, supported by robust cash flow and profitability. Risks include rising debt levels, with debt-to-asset ratio increasing to 47.6% in 2025, and sensitivity to interest rate changes. Analyst sentiment is bullish with 66.66% buy ratings, but technical weakness near 52-week lows warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
